SCHEMBL6712342

SCHEMBL6712342

O=C1Cc2cc3ccccc3n2CCN1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.58
HTR2C P28335 6/20 0.58
NOTUM Q6P988 1/20 0.45
SIGMAR1 Q99720 9/20 0.41
HTR1A P08908 1/20 0.40
PARP1 P09874 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30684257 0.75 HTR2A (0.56) HTR2AHTR2CNOTUMSIGMAR1HTR1A
SCHEMBL10735669 0.75 HTR2A (0.56) HTR2AHTR2CNOTUMSIGMAR1HTR1A
SCHEMBL1393632 0.74 RPS6KA3 (0.53) HTR2AHTR2CPARP1
SCHEMBL30172384 0.74 RPS6KA3 (0.53) HTR2AHTR2CPARP1
SCHEMBL2356686 0.73 HTR2A (1.00) HTR2AHTR2CNOTUMSIGMAR1HTR1A
SCHEMBL18911629 0.73 HTR2A (0.54) HTR2AHTR2CNOTUMSIGMAR1PARP1
Hydrochloric Acid SCHEMBL7842672 0.72 HTR2A (0.97) HTR2AHTR2CNOTUMSIGMAR1HTR1A
SCHEMBL6711152 0.72 HTR2A (1.00) HTR2AHTR2CNOTUMSIGMAR1
SCHEMBL29391845 0.72 HTR2A (1.00) HTR2AHTR2CNOTUMSIGMAR1
SCHEMBL13403405 0.71 NOTUM (0.47) HTR2AHTR2CNOTUMSIGMAR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed
US-4673674-A Diazepinoindoles useful for treating depression, schizophrenia, social withdrawal or anxiety and pharmaceutical compositions containing them SANDOZ PHARMACEUTICALS CORP. (US) 1987-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885NOTUM 3898/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885NOTUM 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.